Volume 53, Issue 37 pp. 9841-9845
Communication

Targeting Human C-Type Lectin-like Molecule-1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia

Dr. Hua Lu

Dr. Hua Lu

Department of Chemistry, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

These authors contributed equally to this work.

Search for more papers by this author
Dr. Quan Zhou

Dr. Quan Zhou

Department of Chemistry, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

These authors contributed equally to this work.

Search for more papers by this author
Vishal Deshmukh

Vishal Deshmukh

Department of Chemistry, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

These authors contributed equally to this work.

Search for more papers by this author
Dr. Hardeep Phull

Dr. Hardeep Phull

Scripps Translational Science Institute, 3344 N Torrey Pines Ct, La Jolla, CA 92037 (USA)

Search for more papers by this author
Dr. Jennifer Ma

Dr. Jennifer Ma

California Institute for Biomedical Research, 11119 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Search for more papers by this author
Dr. Virginie Tardif

Dr. Virginie Tardif

Department of Immunology and Microbial Science, The Scripps Research Institute (USA)

Search for more papers by this author
Dr. Rahul R. Naik

Dr. Rahul R. Naik

Division of Hematology and Oncology, Scripps Clinic, 10666 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Search for more papers by this author
Dr. Claire Bouvard

Dr. Claire Bouvard

California Institute for Biomedical Research, 11119 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Search for more papers by this author
Dr. Yong Zhang

Dr. Yong Zhang

California Institute for Biomedical Research, 11119 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Search for more papers by this author
Dr. Seihyun Choi

Dr. Seihyun Choi

Department of Chemistry, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Search for more papers by this author
Dr. Brian R. Lawson

Dr. Brian R. Lawson

Department of Immunology and Microbial Science, The Scripps Research Institute (USA)

Search for more papers by this author
Dr. Shoutian Zhu

Dr. Shoutian Zhu

California Institute for Biomedical Research, 11119 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Search for more papers by this author
Dr. Chan Hyuk Kim

Corresponding Author

Dr. Chan Hyuk Kim

California Institute for Biomedical Research, 11119 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Chan Hyuk Kim, California Institute for Biomedical Research, 11119 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Peter G. Schultz, Department of Chemistry, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Search for more papers by this author
Dr. Peter G. Schultz

Corresponding Author

Dr. Peter G. Schultz

Department of Chemistry, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

California Institute for Biomedical Research, 11119 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Chan Hyuk Kim, California Institute for Biomedical Research, 11119 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Peter G. Schultz, Department of Chemistry, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037 (USA)

Search for more papers by this author
First published: 23 July 2014
Citations: 65

This work is supported by NIH grant R01 GM097206. H.L. is The Jake Wetchler Foundation Fellow for Pediatric Innovation of the Damon Runyon Cancer Research Foundation DRG-2099-11.

Graphical Abstract

A bispecific antibody, αCLL1-αCD3, was synthesized using a genetically encoded unnatural amino acid, and shown to recruit cytotoxic T cells to CLL1-positive cells. The reported results validate the clinical potential of CLL1 as an AML-specific antigen for the generation of bispecific antibodies for the treatment of acute myeloid leukemia (AML).

Abstract

Acute myeloid leukemia (AML), which is the most common acute adult leukemia and the second most common pediatric leukemia, still has a poor prognosis. Human C-type lectin-like molecule-1 (CLL1) is a recently identified myeloid lineage restricted cell surface marker, which is overexpressed in over 90 % of AML patient myeloid blasts and in leukemic stem cells. Here, we describe the synthesis of a novel bispecific antibody, αCLL1-αCD3, using the genetically encoded unnatural amino acid, p-acetylphenylalanine. The resulting αCLL1-αCD3 recruits cytotoxic T cells to CLL1 positive cells, and demonstrates potent and selective cytotoxicity against several human AML cell lines and primary AML patient derived cells in vitro. Moreover, αCLL1-αCD3 treatment completely eliminates established tumors in an U937 AML cell line xenograft model. These results validate the clinical potential of CLL1 as an AML-specific antigen for the generation of a novel immunotherapeutic for AML.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.